A retrospective analysis of tacrolimus pharmacokinetic in Saudi paediatric patients in early post-liver transplantation period.

IF 2.3 4区 医学 Q2 PEDIATRICS
Ashjan Alghanem, Hala Joharji, Noureldeen Garaween, Huda Alenazi, Nada A Alsaleh, Dieter Broering, Mohammed Alshagrani, Fatimah Alhassan, Ahmed A Albassam, Abdullah Alsultan, Abeer Alsmari
{"title":"A retrospective analysis of tacrolimus pharmacokinetic in Saudi paediatric patients in early post-liver transplantation period.","authors":"Ashjan Alghanem, Hala Joharji, Noureldeen Garaween, Huda Alenazi, Nada A Alsaleh, Dieter Broering, Mohammed Alshagrani, Fatimah Alhassan, Ahmed A Albassam, Abdullah Alsultan, Abeer Alsmari","doi":"10.1016/j.pedneo.2024.11.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tacrolimus is an essential immunosuppressive medication in paediatric patients' post-liver transplantation. Achieving tacrolimus target concentration in early post-transplantation is crucial to minimise the risk of acute rejection; however, this is challenging due to inter- and intra-patient variability in tacrolimus metabolism and clearance. Therefore, our study aims to describe tacrolimus trough concentration variability and pharmacokinetics in paediatric post-liver transplantation during the first two weeks post-transplantation.</p><p><strong>Method: </strong>This retrospective multicentre observational study included paediatric patients post-liver transplantation. Post-operative data was collected within the initial 14 days using electronic health records, including daily tacrolimus doses, measured trough concentrations, graft data, surgical data, and documented acute rejection. Pharmacokinetic analysis was completed using the Monolix software. We used the empirical Bayesian estimates of clearance and volume of distribution for covariate testing to assess possible correlations. We performed a stepwise regression analysis (alpha = 0.05).</p><p><strong>Results: </strong>Ninety-one paediatric patients were included in the study, with a mean age of 4.1 years (SD = 4.6). The mean graft-to-recipient weight ratio (GRWR) was 3% (SD = 6). The vast majority of the patients received the liver from living donors (n = 84, 92.3%). The average time needed to reach therapeutic concentration was 4.6 (SD = 2.8) days. The initial clearance (Clini) was very low at baseline (0.012 L/h), then increased dramatically to 9.84 L/h at 14 days post-transplantation. The clearance appeared to be time-dependent, and the time needed to reach 50% of maximum clearance was five days post-transplantation. The covariates that significantly affected clearance included bodyweight and aspartate transaminase, while the only significant covariate for volume of distribution was bodyweight.</p><p><strong>Conclusion: </strong>Tacrolimus is a drug with high intra- and interindividual variability, making dosing challenging in the paediatric liver transplantation population. Prospective studies with more intensive sampling are needed to address the time-dependent changes in clearance, which will aid in establishing the optimal dosing regimens in this population.</p>","PeriodicalId":56095,"journal":{"name":"Pediatrics and Neonatology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatrics and Neonatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.pedneo.2024.11.001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tacrolimus is an essential immunosuppressive medication in paediatric patients' post-liver transplantation. Achieving tacrolimus target concentration in early post-transplantation is crucial to minimise the risk of acute rejection; however, this is challenging due to inter- and intra-patient variability in tacrolimus metabolism and clearance. Therefore, our study aims to describe tacrolimus trough concentration variability and pharmacokinetics in paediatric post-liver transplantation during the first two weeks post-transplantation.

Method: This retrospective multicentre observational study included paediatric patients post-liver transplantation. Post-operative data was collected within the initial 14 days using electronic health records, including daily tacrolimus doses, measured trough concentrations, graft data, surgical data, and documented acute rejection. Pharmacokinetic analysis was completed using the Monolix software. We used the empirical Bayesian estimates of clearance and volume of distribution for covariate testing to assess possible correlations. We performed a stepwise regression analysis (alpha = 0.05).

Results: Ninety-one paediatric patients were included in the study, with a mean age of 4.1 years (SD = 4.6). The mean graft-to-recipient weight ratio (GRWR) was 3% (SD = 6). The vast majority of the patients received the liver from living donors (n = 84, 92.3%). The average time needed to reach therapeutic concentration was 4.6 (SD = 2.8) days. The initial clearance (Clini) was very low at baseline (0.012 L/h), then increased dramatically to 9.84 L/h at 14 days post-transplantation. The clearance appeared to be time-dependent, and the time needed to reach 50% of maximum clearance was five days post-transplantation. The covariates that significantly affected clearance included bodyweight and aspartate transaminase, while the only significant covariate for volume of distribution was bodyweight.

Conclusion: Tacrolimus is a drug with high intra- and interindividual variability, making dosing challenging in the paediatric liver transplantation population. Prospective studies with more intensive sampling are needed to address the time-dependent changes in clearance, which will aid in establishing the optimal dosing regimens in this population.

沙特儿童肝移植术后早期他克莫司药代动力学回顾性分析。
背景:他克莫司是儿童肝移植后必不可少的免疫抑制药物。在移植后早期达到他克莫司靶浓度对于降低急性排斥反应的风险至关重要;然而,由于他克莫司代谢和清除率在患者间和患者内部的可变性,这是具有挑战性的。因此,我们的研究旨在描述他克莫司在儿童肝移植术后头两周内的浓度变异性和药代动力学。方法:这项回顾性多中心观察性研究纳入了肝移植后的儿科患者。术后数据在最初的14天内使用电子健康记录收集,包括每日他克莫司剂量、测量的谷浓度、移植数据、手术数据和记录的急性排斥反应。采用Monolix软件进行药代动力学分析。我们使用经验贝叶斯估计清除率和分布量的协变量检验来评估可能的相关性。我们进行逐步回归分析(alpha = 0.05)。结果:91例儿童患者纳入研究,平均年龄4.1岁(SD = 4.6)。平均移植物与受体重量比(GRWR)为3% (SD = 6)。绝大多数患者接受活体供体肝脏(n = 84, 92.3%)。达到治疗浓度所需的平均时间为4.6 (SD = 2.8)天。初始清除率(Clini)在基线时非常低(0.012 L/h),然后在移植后14天急剧增加到9.84 L/h。清除似乎是时间依赖性的,达到最大清除率的50%所需的时间是移植后5天。显著影响清除率的协变量包括体重和天冬氨酸转氨酶,而唯一显著影响分布体积的协变量是体重。结论:他克莫司是一种具有高度个体内和个体间变异性的药物,在儿童肝移植人群中给药具有挑战性。需要进行更密集采样的前瞻性研究,以解决清除率随时间的变化,这将有助于在该人群中建立最佳给药方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
170
审稿时长
48 days
期刊介绍: Pediatrics and Neonatology is the official peer-reviewed publication of the Taiwan Pediatric Association and The Society of Neonatology ROC, and is indexed in EMBASE and SCOPUS. Articles on clinical and laboratory research in pediatrics and related fields are eligible for consideration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信